BioXcel Therapeutics (BTAI) Accumulated Expenses (2017 - 2026)

BioXcel Therapeutics' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 4890.62% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $6.4 million, a 4890.62% increase from a year earlier, with the FY2025 full-year figure at $34000.0, down 2.86% from the prior year.
• Accumulated Expenses advanced to $6.4 million in Q1 2026 per BTAI's latest filing, from $34000.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $26.6 million in Q3 2023 and bottomed at $34000.0 in Q4 2025.
• The 5-year median for Accumulated Expenses is $1.9 million (2022), against an average of $5.7 million.
• Across the five-year window, Accumulated Expenses tumbled 99.85% in 2024 and surged 11087.18% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $3.2 million in 2022, then slumped by 76.82% to $736000.0 in 2023, then sank by 95.24% to $35000.0 in 2024, then declined by 2.86% to $34000.0 in 2025, then jumped by 18688.24% to $6.4 million in 2026.
• Per Business Quant, the three latest BTAI Accumulated Expenses figures stand at $6.4 million (Q1 2026), $34000.0 (Q4 2025), and $4.4 million (Q3 2025).